SARS-CoV-2 immunity: review and applications to phase 3 vaccine candidates
Elemento
Click for External Resource*
Click to read full article*
*The link above may share a zip file (.zip) hosted on repository.netecweb.org. Zip files will download automatically.
*All other links are external and will open in a new window. If you click an external link, you are leaving the NETEC site, and we do not maintain, review, or endorse these materials. See our terms of use.
Item Type
PublicaciónTerms of Use
By accessing these materials you are agreeing to our terms of use, which may be found here: Terms of Use.
Título
SARS-CoV-2 immunity: review and applications to phase 3 vaccine candidates
Materia
Descripción
Understanding immune responses to severe acute respiratory syndrome coronavirus 2 is crucial to understanding disease pathogenesis and the usefulness of bridge therapies, such as hyperimmune globulin and convalescent human plasma, and to developing vaccines, antivirals, and monoclonal antibodies.
Fecha
2020-10-13
Tipo
Citación
Poland, Gregory A., Inna G. Ovsyannikova, and Richard B. Kennedy. 2020. "SARS-CoV-2 immunity: review and applications to phase 3 vaccine candidates." The Lancet.
Resumen
Summary
Understanding immune responses to severe acute respiratory syndrome coronavirus 2 is crucial to understanding disease pathogenesis and the usefulness of bridge therapies, such as hyperimmune globulin and convalescent human plasma, and to developing vaccines, antivirals, and monoclonal antibodies. A mere 11 months ago, the canvas we call COVID-19 was blank. Scientists around the world have worked collaboratively to fill in this blank canvas. In this Review, we discuss what is currently known about human humoral and cellular immune responses to severe acute respiratory syndrome coronavirus 2 and relate this knowledge to the COVID-19 vaccines currently in phase 3 clinical trials.
Accesibilidad
Free online on Lancet site.
Was this resource helpful?